Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Sp...

por Hidalgo-Vega, Álvaro, Villoro, Renata, Blasco, Juan Antonio, Talavera, Pablo, Ferro, Belén, Purcaru, Oana
Publicado 2015